Literature DB >> 21641761

Gender is a significant factor for failure of metal-on-metal total hip arthroplasty.

Michael J Latteier1, Keith R Berend, Adolph V Lombardi, Andrew F Ajluni, Brian E Seng, Joanne B Adams.   

Abstract

Metal-on-metal (MoM) articulations offers low wear, larger head size, and increased stability. Reports of early failure are troubling and include failure of ingrowth and metal articulation problems such as metallosis, hypersensitivity, pseudotumor, and unexplained pain. This study investigates the survivorship of modern MoM articulations by gender. We reviewed 1589 primary MoM THA in 1363 patients, with minimum 2-year follow-up for 1212 hips. Follow-up averaged 60 months. There were 643 female patients and 719 male patients. The incidence of cup revision was significantly higher in women than in men (8.2% vs 2.7%; P = .0000), as was incidence of aseptic loosening (4.3% vs 1.1%; P = .0006), and failure for metal-bearing complications (2.2% vs 0.6%; P = .0126). There appear to be gender factors influencing the success of MoM THA, which may include hormonal, anatomic, or functional differences.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641761     DOI: 10.1016/j.arth.2011.04.012

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  14 in total

1.  Large-diameter metal-on-metal total hip arthroplasty: dislocation infrequent but survivorship poor.

Authors:  Adolph V Lombardi; Keith R Berend; Michael J Morris; Joanne B Adams; Michael A Sneller
Journal:  Clin Orthop Relat Res       Date:  2014-11-04       Impact factor: 4.176

2.  CORR Insights(®): do patients with a failed metal-on-metal hip implant with a pseudotumor present differences in their peripheral blood lymphocyte subpopulations?

Authors:  Nadim James Hallab
Journal:  Clin Orthop Relat Res       Date:  2015-12       Impact factor: 4.176

3.  CORR Insights®: Frank Stinchfield Award: Identification of the At-risk Genotype for Development of Pseudotumors Around Metal-on-metal THAs.

Authors:  Nikolaos V Bardakos
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

4.  Comparison of metal ion levels in patients with hip resurfacing versus total hip arthroplasty.

Authors:  Craig W Forsthoefel; Nicholas M Brown; Mark L Barba
Journal:  J Orthop       Date:  2017-08-31

5.  The effect of contact load on CoCrMo wear and the formation and retention of tribofilms.

Authors:  M A Wimmer; M P Laurent; M T Mathew; C Nagelli; Y Liao; L D Marks; J J Jacobs; A Fischer
Journal:  Wear       Date:  2015 May-Jun       Impact factor: 3.892

6.  Adverse Reactions to Metal on Metal Are Not Exclusive to Large Heads in Total Hip Arthroplasty.

Authors:  Adolph V Lombardi; Keith R Berend; Joanne B Adams; Keri L Satterwhite
Journal:  Clin Orthop Relat Res       Date:  2016-02       Impact factor: 4.176

7.  Metal-on-metal hip resurfacing compared with total hip arthroplasty: two to five year outcomes in men younger than sixty five years.

Authors:  Leslie A Fink Barnes; Skylar H Johnson; David A Patrick; William Macaulay
Journal:  Int Orthop       Date:  2014-09-25       Impact factor: 3.075

Review 8.  Sequelae of large-head metal-on-metal hip arthroplasties: Current status and future prospects.

Authors:  Christiaan P van Lingen; Luigi M Zagra; Harmen B Ettema; Cees C Verheyen
Journal:  EFORT Open Rev       Date:  2017-03-13

9.  Perfusion MRI in hips with metal-on-metal and metal-on-polyethylene total hip arthroplasty: A pilot study.

Authors:  H Anwander; G O Cron; K Rakhra; P E Beaule
Journal:  Bone Joint Res       Date:  2016-03       Impact factor: 5.853

Review 10.  Prevalence of Failure due to Adverse Reaction to Metal Debris in Modern, Medium and Large Diameter Metal-on-Metal Hip Replacements--The Effect of Novel Screening Methods: Systematic Review and Metaregression Analysis.

Authors:  Aleksi Reito; Olli Lainiala; Petra Elo; Antti Eskelinen
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.